使用BTK抑制剂TL-895的药物相互作用负担
Jack C Stromatt1, Eman A Ahmed1, Thomas Drabison1
1The Ohio State University, Columbus, Ohio, United States.
Cancer research communications
|August 22, 2025
概括
这是一种双BTK/ BMX抑制剂,具有强烈的BMX抑制作用. 它是OATP1B1和CYP3A4的基质,但不太可能引起药物相互作用,确保在组合治疗中使用更安全.
科学领域:
- 药理学
- 药物代谢和药物动力学
- 癌症学
背景情况:
- 对于新疗法的药物相互作用 (DDI) 有限的早期数据.
- 对于药物的安全性和有效性来说,了解非向作用和输送剂/酶相互作用至关重要.
研究的目的:
- 描述TL-895的激酶相互作用特征.
- 评估TL-895作为OATP1B1和CYP3A4基质的药物相互作用 (DDI).
主要方法:
- 使用激酶抑制试验 (IC50) 和BRET试验来确定酶抑制.
- 使用体外和体内模型评估OATP1B1和CYP3A4的DDI潜力.
- 在CYP3A- null小鼠中进行了药理动力学研究,以评估酶介导相互作用.
主要成果:
- 对于Bmx (IC50:0. 53nM),TL-895具有较强的抑制作用,抑制布鲁顿氨酸激酶 (BTK) 和Bmx.
- TL-895被确定为肝脏输送物OATP1B1和CYP3A4酶的基质.
- TL-895没有增加OATP1B1基质的血度,
- 抑制CYP3A4导致CYP3A零小鼠的TL-895度增加,证实了CYP3A4在代谢中的作用.
结论:
- TL-895是一种双BTK/ BMX抑制剂,具有明确的激酶相互作用特征.
- 在体内,OATP1B1和CYP3A4对TL-895的分离有显著的作用.
- TL-895不太可能是临床显著的OATP1B1介导的DDI,支持其在多药疗法中的潜在使用.
相关概念视频
Factors Affecting Protein-Drug Binding: Drug Interactions
273
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
273
Combined Effects of Drugs: Antagonism
9.2K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
9.2K
Protein-Drug Binding: Mechanism and Kinetics
931
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
931
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Drug Distribution: Tissue Binding
3.2K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
3.2K


